Board

David Fellows Chair

David is the CEO of AGTC and Chair of the Oxular Board. He has more than 30 years of experience in various leadership roles within the ophthalmic pharmaceutical industry. He was previously CEO of Nightstar Therapeutics, a private biopharmaceutical company specialising in developing ocular gene therapies for patients with inherited retinal dystrophies, with David leading the company through a successful NASDAQ listing and M&A transaction. He was previously Vice President of Johnson …

David Fellows Chair Read More »

Dr. Dmitrij Hristodorov Director

Dmitrij is Partner at Forbion where, as a core member of the investment team, he contributes to investments across various stages, treatment modalities and diseases. Previously, he was Senior Director of Global Business Development & Licensing at Bayer Pharma, where he was responsible for ophthalmology, cardiology, nephrology, and pulmonology. Dmitrij currently serves as a board …

Dr. Dmitrij Hristodorov Director Read More »

Dr. Sam Williams

Sam has over 30 years’ experience in the Life Sciences sector as a scientist, company CEO and investment manager. He is currently Managing Partner at IP Group plc., the FTSE 250 investor, where he oversees the group’s c.£500m Life Sciences portfolio. He is founding CEO and Chairman of Istesso Ltd, a Phase 2 drug-discovery company, …

Dr. Sam Williams Read More »

Dr. Kenneth Macleod, PhD

Kenneth is a Partner at Rosetta Capital, a venture capital firm focussed on the life sciences and medical devices . Ken has over 35 years’ experience in the life sciences sector in a career combining senior operating roles in healthcare companies (Abbott Labs., Serono SA) and life science fund management (SV Health Investors, Paul Capital, …

Dr. Kenneth Macleod, PhD Read More »

Christina Takke, PhD Director

Christina is co-founder and Managing Director of V-Bio Ventures. With more than 20 years of investment experience in European venture capital, Christina was previously a partner with Forbion Capital Partners (formerly ABN AMRO Capital) where she led and managed a series of successful biotech investments since 2001. Christina currently serves on the boards of Confo …

Christina Takke, PhD Director Read More »

Dr. Rafiq Hasan Director

Rafiq is the CEO of Complement Therapeutics, a life sciences company aiming to develop the next generation of complement medicines. Rafiq has pursued a successful career in the pharmaceutical industry globally, including senior positions in ophthalmology with Bayer and Novartis. Most recently as Senior Vice President and Global Head of Ophthalmology at Bayer, Rafiq grew …

Dr. Rafiq Hasan Director Read More »

Mark Gaffney – Chief Executive Officer

Mark has 20+ years of leadership experience in biotech & life sciences. He is motivated to find durable and safe treatments for blindness, influenced by his father’s retinitis pigmentosa. A former U.S. Air Force intelligence officer, Mark’s analytical problem-solving approach is backed by degrees in mechanical engineering and law. His dedication to innovation aims to …

Mark Gaffney – Chief Executive Officer Read More »

Scroll to Top